These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 15802193

  • 21. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 22. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.
    Biol Psychiatry; 2009 Sep 15; 66(6):603-13. PubMed ID: 19520364
    [Abstract] [Full Text] [Related]

  • 23. Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
    Billet F, Costentin J, Dourmap N.
    Exp Neurol; 2012 Aug 15; 236(2):339-50. PubMed ID: 22575599
    [Abstract] [Full Text] [Related]

  • 24. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes.
    Odagaki Y, Toyoshima R.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep 30; 30(7):1304-12. PubMed ID: 16824659
    [Abstract] [Full Text] [Related]

  • 25. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 30; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 26. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2013 Oct 30; 73():216-31. PubMed ID: 23756168
    [Abstract] [Full Text] [Related]

  • 27. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, Gross CE, Crossman AR, Bloch B, Bezard E.
    Biol Psychiatry; 2007 Apr 01; 61(7):836-44. PubMed ID: 16950226
    [Abstract] [Full Text] [Related]

  • 28. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
    Hosohata K, Varga EV, Alfaro-Lopez J, Tang X, Vanderah TW, Porreca F, Hruby VJ, Roeske WR, Yamamura HI.
    J Pharmacol Exp Ther; 2003 Feb 01; 304(2):683-8. PubMed ID: 12538822
    [Abstract] [Full Text] [Related]

  • 29. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 30. Mu opioid receptor coupling to Gi/o proteins increases during postnatal development in rat brain.
    Talbot JN, Happe HK, Murrin LC.
    J Pharmacol Exp Ther; 2005 Aug 01; 314(2):596-602. PubMed ID: 15860573
    [Abstract] [Full Text] [Related]

  • 31. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar 01; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 32. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 01; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 33. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
    Calon F, Lavertu N, Lemieux AM, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T.
    Synapse; 2001 Jun 01; 40(3):225-34. PubMed ID: 11304760
    [Abstract] [Full Text] [Related]

  • 34. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA, Morin N, Grégoire L, Morissette M, Di Paolo T.
    J Neurosurg; 2015 Dec 01; 123(6):1383-93. PubMed ID: 25932606
    [Abstract] [Full Text] [Related]

  • 35. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
    Cox H, Togasaki DM, Chen L, Langston JW, Di Monte DA, Quik M.
    Exp Neurol; 2007 May 01; 205(1):101-7. PubMed ID: 17335811
    [Abstract] [Full Text] [Related]

  • 36. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Mov Disord; 2006 Jan 01; 21(1):9-17. PubMed ID: 16127720
    [Abstract] [Full Text] [Related]

  • 37. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep 01; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 38. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X.
    Neurobiol Aging; 2010 Jun 01; 31(6):926-36. PubMed ID: 18707801
    [Abstract] [Full Text] [Related]

  • 39. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY, Friedman E, Olmstead MC, Burns LH.
    Neuroscience; 2005 Jun 01; 135(1):247-61. PubMed ID: 16084657
    [Abstract] [Full Text] [Related]

  • 40. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C, Jiménez A, Tolosa E, Bonastre M, Bové J.
    Synapse; 2004 Feb 01; 51(2):140-50. PubMed ID: 14618681
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.